Developing organoids from breast cancer tissue
Developing Breast (Cancer) Organoids
This study is trying to create mini versions of breast cancer tumors from patient samples to see how they can help doctors understand the disease better and choose the best treatments for each person.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Maastricht Radiation Oncology Academic / other |
| Locations | 1 site (Maastricht) |
| Trial ID | NCT05317221 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a living biobank of breast cancer organoids derived from patient tissue samples collected during routine surgical procedures. By obtaining small samples of excised tumors and blood for genetic analysis, the study seeks to understand how these organoids reflect disease progression, treatment response, and relapse across different breast cancer subtypes. The goal is to develop a patient-tailored clinical model that addresses tumor heterogeneity and guides individualized treatment selection without altering the standard care process for participants.
Who should consider this trial
Good fit: Ideal candidates are female patients over 18 years old with a confirmed diagnosis of breast cancer who are undergoing primary surgery.
Not a fit: Patients who are physically or mentally incapable of providing informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment strategies for breast cancer patients.
How similar studies have performed: Other studies have shown promise in using organoids for drug response screening, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female, * \>18 years, * Family Anamneses * Breast cancer (proven by histopathology), Included subtypes; (ER-,PR- HER2-); (ER+, PR+, HER2-); (ER+, PR+ HER2+). * Primary surgery (lumpectomy or mastectomy) Exclusion Criteria: \- Physically or mentally incapable or incompetent to sign informed consent
Where this trial is running
Maastricht
- Maastricht University Medical Center — Maastricht, Netherlands (Recruiting)
Study contacts
- Principal investigator: Marc Vooijs, PhD — Maastricht University
- Study coordinator: Chantal Overhof
- Email: chantal.overhof@maastro.nl
- Phone: +31 88 44 55 683
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.